Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases in the UK and internationally. The company is headquartered in London, the United Kingdom.
52W High
$4.72
52W Low
$1.47
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.41
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.21
EV/Revenue (<3 favorable)
452.15
P/S (TTM) (<3 favorable)
563.20
P/B (<3 favorable)
5.20
Ownership
BalancedSource: Overview
Insiders (1–5% typical)
0.96%
Institutions (25–75% balanced)
69.08%
Shares Outstanding
159,097,000
Float
502,348,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
500,000
Gross Profit (TTM)
368,000
EPS (TTM)
-0.30
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-19.51%
ROE (TTM) (>15% strong)
-0.75%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—